Analyst Phil Nadeau from TD Cowen maintained a Buy rating on Neurocrine and increased the price target to $170.00 from $165.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Phil Nadeau has given his Buy rating due to a combination of factors that highlight Neurocrine’s strong growth potential. The company reported impressive Q2 revenue for its Crenessity product, significantly surpassing market expectations with a 267% quarter-over-quarter increase. This robust performance is attributed to successful campaigns that have enhanced clinician and patient awareness, leading to a higher-than-anticipated adoption rate.
Furthermore, despite some pricing pressures, Ingrezza’s revenue met consensus estimates, and the company continues to experience record patient starts. Neurocrine’s strategic initiatives, including an expanded field force and direct-to-consumer campaigns, are expected to drive further growth. These factors, coupled with an increased price target from $165 to $170, underscore the positive outlook for Neurocrine, justifying the Buy rating.
In another report released on July 28, Morgan Stanley also maintained a Buy rating on the stock with a $150.00 price target.